Abstract
The azetidinone core-structure offers a unique approach to the design and synthesis of new derivatives with unique biological properties. During the last two decades researches convincingly demonstrated that the prospect of structural modifications of monocyclic β-lactams with specific substituents is an effective procedure for the detection and improvement of important pharmacological effects different from antibacterial activity. As a matter of fact, new β-lactam compounds demonstrated biological activity as inhibitors of a wide range of enzymes. This review reports the latest developments on monocyclic β-lactam compounds activity as anticancer, antitubercular, HFAAH inhibitors, HDAC inhibitors, anti-inflammatory drugs (tryptase inhibitors), Cathepsin K inhibitors, and vasopressin inhibitors. We attempted to highlight the intertwined relationships between structural features and biological activities, by analysing groups anchored on the three positions of the azetidinone ring as sources of molecular diversity
Keywords: Antibacterial, antibiotics, anticancer, azetidinone, heterocycles, β-lactam, inhibitor activity, enzymatic inhibitors, HFAAH, tryptase, cathepsin, HDAC, PPAR, monocyclic β-lactams, biological activity
Current Medicinal Chemistry
Title: Monocyclic β-Lactams: New Structures for New Biological Activities
Volume: 18 Issue: 28
Author(s): P. Galletti and D. Giacomini
Affiliation:
Keywords: Antibacterial, antibiotics, anticancer, azetidinone, heterocycles, β-lactam, inhibitor activity, enzymatic inhibitors, HFAAH, tryptase, cathepsin, HDAC, PPAR, monocyclic β-lactams, biological activity
Abstract: The azetidinone core-structure offers a unique approach to the design and synthesis of new derivatives with unique biological properties. During the last two decades researches convincingly demonstrated that the prospect of structural modifications of monocyclic β-lactams with specific substituents is an effective procedure for the detection and improvement of important pharmacological effects different from antibacterial activity. As a matter of fact, new β-lactam compounds demonstrated biological activity as inhibitors of a wide range of enzymes. This review reports the latest developments on monocyclic β-lactam compounds activity as anticancer, antitubercular, HFAAH inhibitors, HDAC inhibitors, anti-inflammatory drugs (tryptase inhibitors), Cathepsin K inhibitors, and vasopressin inhibitors. We attempted to highlight the intertwined relationships between structural features and biological activities, by analysing groups anchored on the three positions of the azetidinone ring as sources of molecular diversity
Export Options
About this article
Cite this article as:
Galletti P. and Giacomini D., Monocyclic β-Lactams: New Structures for New Biological Activities, Current Medicinal Chemistry 2011; 18 (28) . https://dx.doi.org/10.2174/092986711797200480
DOI https://dx.doi.org/10.2174/092986711797200480 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Current Medicinal Chemistry Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma
Current Pharmaceutical Design Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Cardiac Remodeling Induced by Smoking: Concepts, Relevance, and Potential Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) In Silico Design of Fusion Toxin DT<sub>389</sub>GCSF and a Comparative Study
Current Computer-Aided Drug Design Editorial: [Cytokines as Anti-Cancer Agents Rational, Results and Perspectives (Guest Editor: S. Mocellin)]
Current Medicinal Chemistry Structural Characterization of Carbohydrates by Fourier Transform Tandem Mass Spectrometry
Current Proteomics Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry 5-Lipoxygenase: Cellular Biology and Molecular Pharmacology
Current Drug Targets - Inflammation & Allergy Activating Mutations of ESR1, BRCA1 and CYP19 Aromatase Genes Confer Tumor Response in Breast Cancers Treated with Antiestrogens
Recent Patents on Anti-Cancer Drug Discovery Study in Treatment of Collagen-Induced Arthritis in DBA/1 Mice Model by Genistein
Current Pharmaceutical Design GPR30 Forms an Integral Part of E2-Protective Pathway in Experimental Autoimmune Encephalomyelitis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Helicobacter Pylori, Zinc and Iron in Oxidative Stress-Induced Injury of Gastric Mucosa
Mini-Reviews in Medicinal Chemistry Potential of Selected Antioxidants for Influenza Chemotherapy
Anti-Infective Agents in Medicinal Chemistry Short Bioactive Marine Oligosaccharides: Diving into Recent Literature
Current Biotechnology Subject Index to Volume 4
Mini-Reviews in Medicinal Chemistry Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design Editorial (Hot Topic:Depression and Serotonin: A Never Ending Story)
Current Drug Targets